The 5th China US Nanomedicine and Nanobiotechnology Annual Conference will be held in Guangzhou from December 8th to 10th, 2023. This annual conference is hosted by the China US Society for Nanomedicine and Nanobiotechnology (CASNN) and organized by South China University of Technology and Zhejiang University. It brings together academicians, experts, and young talents from China, the United States, and other countries and regions to fully discuss the bottlenecks and challenges faced by the global nanomedicine and nanobiotechnology fields, stimulate new ideas, transform new technologies, further enhance the level of interdisciplinary integration, promote industrial transformation, and create a better life.

Cross disciplinary research "has been a hot topic in international nanomedicine in recent years, among which nanomedicine based on poly (propylene glycol) copolymer (PLGA) carrier provides enormous opportunities for biomedical research. Guangzhou Diqi, as the only domestic enterprise with dual reporting of PLGA between China and the United States, has long been committed to providing efficient and safe high-end excipients for global pharmaceutical companies. It actively explores a series of drugs based on PLGA as a carrier for long-acting and nano formulations, and achieves higher compliance, better efficacy, lower adverse reactions, and lower recurrence rates through long-acting delivery technology to achieve clinical value of drugs. At this conference, experts and researchers from multiple universities, research institutes, enterprises, and other institutions had in-depth exchanges with Diqi on the development and application of poly (propylene glycol) copolymers.

Dr. Liu Feng, founder and general manager of Guangzhou Diqi, attended the annual meeting and delivered a keynote speech on the application of polylactide and its copolymers in complex formulations.

Poly (lactide co glycolide), abbreviated as PLG; Poly - (d, l-lactide-co-glycolide), also commonly referred to as PLGA in literature, is a high molecular weight polymer composed of units of propylene glycol and ethylene glycol. It can be classified into different types such as 8515, 7525, 5050 based on the ratio of these two monomers in the molecular chain. Due to their similar physicochemical and biological properties, different types of PLGA can be considered as the same class of substances.

At present, innovative biopharmaceutical products based on PLGA have been approved by drug regulatory authorities in multiple countries including the United States, Europe, and China, and are widely used in clinical treatment and medical diagnosis. Through the first-class technology exchange platform of the China US Nanomedicine and Nanobiotechnology Society, as well as a group of innovative enterprises represented by Guangzhou Diqi, the application of polylactide polymers has been further promoted, promoting the development and application of cross disciplinary research in the field of nanotechnology, and enhancing the international influence of China's nanomedicine technology.